PAVMWライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 1月 2022 @ 02:36):

Stats
本日の出来高	32 626
平均出来高	6 563
時価総額	769 747
EPS	$-1.750 ( Q1 \| 2024-05-13 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0500 (Sector) 42.63 (Industry) 43.86
ATR14	$0.0950 (327.59%)

ABMD 0.00%

AMIX -4.95%

BBLGW -21.85%

BVS 0.52%

COCH 3.06%

DHAI -3.26%

DHAIW -22.93%

DNAY 8.33%

EYES -5.05%

GBS -1.58%

HSCS -1.70%

HSCSW -32.26%

IINNW 1.61%

INVO -3.33%

LFWD 1.26%

MDAI -2.22%

MGRM 3.86%

MXCT -2.00%

NVNOW -32.98%

NXL -42.91%

NXLIW -15.00%

OSA -7.35%

OSAAW -6.40%

PAVMW 105.67%

PAVMZ 0.00%

PETVW 0.00%

QTI 2.21%

QTNT 0.00%

ボリューム相関

長: -0.02 (neutral)

短: -0.15 (neutral)

Signal:(30.313) Neutral

PAVmed Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

PAVmed Inc. 相関 - 通貨/商品

0.78
( moderate )

-0.46
( neutral )

-0.05
( neutral )

0.17
( neutral )

0.59
( weak )

-0.63
( weak negative )

PAVmed Inc. 財務諸表

Annual	2023
収益:	$2.45M
総利益:	$-6.90M (-281.40 %)
EPS:	$-8.87

FY	2023
収益:	$2.45M
総利益:	$-6.90M (-281.40 %)
EPS:	$-8.87

FY	2022
収益:	$377 000
総利益:	$-3.24M (-858.62 %)
EPS:	$-17.06

FY	2021
収益:	$500 000
総利益:	$-85 000.00 (-17.00 %)
EPS:	$-1.897

Financial Reports:

No articles found.

PAVmed Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

PAVmed Inc.

PAVmed Inc. operates as a medical device company in the United States. The company\'s lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett\'s Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.